Mice homozygous for the spontaneous neuromuscular degeneration (nmd-2J) mutation exhibit motor neuron degeneration leading to atropy of skeletal muscle fibers as early as postnatal week 2. Locomotor impairment progresses to paralysis, usually beginning in the hindlimbs. Most homozygous mutants die by 3.5-4 weeks of age. This strain is useful in studies of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).Read More +
Motor neuron diseases like amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are typified by the degeneration of alpha motor neurons in the spinal cord that subsequently leads to muscle atrophy. The nature of such neuromuscular disorders appears to be complex but spontaneous mouse mutants are helping to pinpoint critical genetic variables. The mouse neuromuscular degeneration nmd mutant mice express an autosomal recessive neurological disease where motor neurons degenerate causing the skeletal muscle fibers to atrophy. Behaviorally, these mice are easily identifiable by the second postnatal week. The hindlimbs are dorsally contracted and their locomotor activity is impaired, but balance is not adversely affected. They cannot extend their legs to stand erect or assume full posture on all four limbs. Homozygotes clench their hindlimbs when picked up by the tail and they are unable to grasp a cage cover when held against it. They can maintain proper balance, however, and do not circle, bob their heads, or fall over sideways. Paralysis usually begins in the hindlimbs and later develops in the forelimbs as the disease progresses. Most homozygous mutants die by 3.5-4 weeks of age. Heterozygotes are phenotypically and histologically normal.
The mutant phenotype is very similar to that seen in the human diseases ALS and SMA. The pathology displayed by the degenerating neurons in both species appears similar in that the affected cells seem to "fade away", or stain more lightly for hematoxylin and eosin (H&E) and luxol fast blue-cresylecht violet (LFB-CV). The "fading away" neurons are not swollen, rather the cytoplasmic and nuclear organelles, while normal in structure, appear less densely packed. The populations of motor neurons that are most highly affected by the mouse nmd alleles are those found in the lumbar region, whereas the neurons in the thoracic and cervical spinal cord regions appear primarily normal. Degenerating alpha motor neurons are also found in the sympathetic chain. The muscle fiber lesions contain a mixture of tiny muscle fibers and normally sized fibers. Compared to the proximal muscle groups, the distal musculature of the forelimbs and hindlimbs contain more severe atrophic lesions with adipose tissue abnormally appearing in some instances. The pathology appears limited to neuromuscular aspects since inflammatory and gliotic responses to the lesions are not detected. The overall pattern of muscle denervation and atrophy appears to be random. Finally, it is not clear why the motor neurons are selectively sensitive to the significantly reduced levels of IGHMBP2 given that this DNA binding protein is widely expressed across many cell types. DNA sequencing reveals the (nmd-2J) mutation has a single A to G transition in intron 4 which results in a cryptic splice donor (interfering with the normal transcript splicing) and produces an abnormally spliced transcript with an additional 23bp and a premature stop codon. RT-PCR analysis of various tissues, including brain and spinal cord, shows that the abnormal mutant splicing produces 20-25% wildtype splicing and 75-80% mutant splicing. (Cook et al., 1995; Cox et al., 1998; Schmalbruch et al., 1991; Grohmann et al., 2001; Mizuta et al., 1993; Chen et al., 1997; Zhang et al., 1999).
The Ighmbp2nmd-2J/Ighmbp2nmd-2J mice arose spontaneously in the BKS.Cg-m +/+ Leprdb (Stock No. 000642) strain at The Jackson Laboratory Mouse Mutant Resource in 1987. These were backcrossed 11 generations to C57BL/6J. At N12, embryos were frozen from male heterozygotes crossed to female C57BL/6J. DNA sequencing reveals the (nmd-2J) mutation has a single A to G transition in intron 4 which results in a cryptic splice donor (interfering with the normal transcript splicing) and produces an abnormally spliced transcript with an additional 23bp and a premature stop codon.
|Allele Name||neuromuscular degeneration 2 Jackson|
|Gene Symbol and Name||Ighmbp2, immunoglobulin mu binding protein 2|
|Strain of Origin||BKS.Cg-Dock7m +/+ Leprdb/J|
|Molecular Note||An A-to-G transition mutation in intron 4 results in the creation of a cryptic splice site and interferes with the normal splicing of the transcript. RT-PCR analysis on RNA derived from various tissues of homozygous mice demonstrated that approximately 20-25% of the transcripts were spliced normally, while 75-80% of the transcripts were spliced aberrantly. This allele also presents with a deletion of one of the two leucine codons at position 362 and 363 in exon 8 (SW:P40694).|
Homozygotes die at about weaning age and must have a foster mother sent along with them.
When using the neuromuscular degeneration 2 Jackson mouse strain in a publication, please cite the originating article(s) and include JAX stock #002521 in your Materials and Methods section.
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.
MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.
Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.